@jcm running a 2.5 years old unsupported version of GNOME is meaningless; to properly evaluate the current state of anything Wayland, you need to be running version 50.3+
"Oh yeah," they thought, "I'm going to write the new official GNOME video player in 1,900 lines of Python, nothing can go wrong", they thought... well, that was until I tried opening a video called "Frankfurter Furry Tram 2025 #Furry #FurDance" in Showtime via Nautilus 😏 https://gitlab.gnome.org/GNOME/showtime/-/work_items/297
Sfaturi pentru a-ți păstra calmul la locul de muncă
Mediul profesional aduce zilnic numeroase oportunități de afirmare și provocări care testează capacitatea de concentrare. Menținerea unei stări de echilibru interior la birou sprijină productivitatea și stimulează creativitatea în rezolvarea sarcinilor complexe. Fiecare zi de lucru devine un spațiu propice pentru exersarea stăpânirii de sine și a calmului absolut. Păstrarea unei atitudini senine în fața termenelor limită strânse sau a cerințelor multiple transformă presiunea profesională în succes.
@sammypanda @bjn Unfortunately GitLab is all-in on AI as much as GitHub. They're maybe just a bit friendlier with their PR, but otherwise it's full technocorpo steam ahead.
@stealthradek I don't think that's yet on the roadmap (and I didn't find an issue describing the idea at https://codeberg.org/comaps/comaps/issues yet)
If you want, you could open an issue suggesting it, but as you mention, it's quite a rare use case. I fear, unless someone with the right skill set to add this runs into the problem themselves, it seems unlikely it'd be prioritised soon.
🧬 Scientists are using mRNA to make cancer cells produce an immune alarm protein called IL-12, and early results are striking.
The idea: inject mRNA encoding IL-12 directly into tumors. The cancer cells produce the protein, which activates T cells and NK cells to attack. Systemic IL-12 was abandoned years ago due to severe toxicity. Local mRNA delivery sidesteps that problem.
Multiple programs are in human trials. AstraZeneca's MEDI1191 showed partial responses in melanoma patients, including those resistant to existing immunotherapy. A Yale preclinical study found a single injection cured 60%+ of mice with melanoma.
There's also a newer approach: molecular on/off switches built into the mRNA itself. Researchers at Mount Sinai (published Nov 2025) engineered mRNA that detects cancer-specific microRNAs and only activates inside tumor cells. In mice: 100-fold higher expression in tumors, 380-fold lower in healthy organs. But this is still preclinical.
The catch: the on/off switch tech is mouse-only so far. The human trials rely on physically injecting into the tumor for selectivity, not molecular switches. Those are two different approaches at different stages, often blended together in popular coverage.
Just happened to notice I merged pull request #1000 for the Micro.blog backend today. About half of those are actually in the last year. I started using PRs way more often when AI could review them for me.
